AOS - TetraFlex Update - Significant Commercial Progress Achieved; Prof. Simon Carroll, Chief Scientific Officer) is available as an Audio file. The following presentation "TetraFlex Update - Significant Commercial Progress Achieved" is now available as an instant audio download to your computer.
GammaCan International (OTCBB: GCAN), and Life Therapeutics (ASX: LFE) today announced a joint effort to develop VitiGam, an innovative anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease, in connection with a grant to be provided by the BIRD Foundation.
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has entered into an agreement with DNA Bioservices Pty. Ltd. to provide paternity testing services to China.
CyGenics Ltd. (ASX: CYN) today formally completed its strategic investment of an initial 20% stake in Dutch-based Pharmacell BV, with an option to purchase the remaining 80% at a later date.
Clinical Cell Culture Ltd (ASX: CCE) today announced that the TGA (Therapeutic Goods Administration) has completed its approval process and ReCell(R) has been placed on the Australian Register of Therapeutic Goods (ARTG).
Clinical Cell Culture Ltd (ASX: CCE) announced that it has appointed Bob Atwill as its new Chief Executive Officer and a Director of the Company. C3's Chief Financial Officer Andrew Cannon also joins the Board.
Life Therapeutics (ASX: LFE) today announced it has secured funding facilities of approximately A$35.3 million with US based investment fund Cornell Capital Partners Offshore LP.
